Advertisement
Advertisement

Seeking financial security, Scripps Research is taking its science directly to patients

Share

One of San Diego’s biomedical powerhouses has entered the drug development business in a big way.

Long dedicated to basic science, The Scripps Research Institute is now also testing its own drugs in people, something typically done by for-profit companies.

A Scripps Research affiliate recently started clinical testing of a drug to reverse osteoarthritis by regenerating cartilage. This painful condition commonly occurs with age or injuries that damage cartilage.

Advertisement

If the drug works, it would not only relieve suffering for millions of people, but ease the financial pain at Scripps Research, or TSRI. The nonprofit has been running annual deficits as high as $20 million in recent years. This poses a challenge to the institute’s long-term stability.

Testing began in May by the California Institute for Biomedical Research, or Calibr. Early signs are that the therapy is safe, said Matt Tremblay, chief operating officer of both Calibr and Scripps Research.

Other therapies expected to enter clinical trials next year will treat different forms of cancer.

Calibr was established in 2012 with $90 million from drug giant Merck to speed translating basic science into therapies. While still performing its own science, Calibr has since become TSRI’s drug development arm.

This is part of the vision of Peter G. Schultz, Scripps Research CEO, who also leads Calibr. If research can be taken into clinical trials, the institute will have more leverage in negotiating deals, Schultz says.

While drug development is extremely risky, just a few major hits could fuel research for years to come, which in turn would generate more successful drugs.

“If I’m successful in putting eight (drugs in the clinic) -- and not all of them but just two (succeed) -- I think that’ll be a billion dollars,” Schultz said in an October 2016 interview.

Earlier this year, Schultz gave himself a timeline, saying his strategy should bring financial security within three to five years. The drugs now entering clinical testing provide early signs this approach may be working.

The institute has recently entered into profitable deals with three medical companies through Calibr, Tremblay said. However, the companies required the financial terms be kept confidential.

Presumably, any financial returns from those and other deals will eventually show up when TSRI files required financial disclosures.

There’s some precedent for what the institute is trying to do. MassBiologics, part of the University of Massachusetts Medical School, has also taken drugs into clinical trials before licensing them. It specializes in vaccines and antibody-based drugs. The difference is that MassBiologics is part of a public university, while TSRI is a private, standalone nonprofit.

Fixing the problem

The arthritis drug is also a personal issue for Schutz, who has wryly discussed his own struggle with arthritic knees.

Tough and slippery, cartilage cushions the ends of bone, allowing them to glide past each other. However, cartilage doesn’t regenerate well. For patients with worn-out joints, alternatives include grafts from cadavers, removal of damaged cartilage, experimental stem cell therapy, and total joint replacement.

None of these alternatives are totally satisfying. Cadaver cartilage is in limited supply, and must be screened for infection. Stem cell therapy yields unreliable results.

And total joint replacements may be infected during implantation, sometimes don’t function well and may cause pain. Moreover, it’s irreversible. Local philanthropist Denny Sanford has publicly complained about his artificial knee, and praised the result of a stem cell treatment he had in Germany.

Scripps Research’s drug could provide a superior alternative by reliably regenerating cartilage without the need for surgery.

The drug, now called KA34, is injected into the knees. In preclinical studies, it caused cells called chondrocytes already present in joints to form new cartilage.

KA34 wasn’t the product of an elaborate study of the intricacies of cartilage formation. It emerged from testing huge numbers of chemicals against chondrocytes, and selecting those that promoted regeneration for further study.

There’s also competition. For example, another cartilage-regenerating drug is now being tested by Novartis.

Assuming risk

Decades ago, Scripps Research gained hundreds of millions of dollars from drug companies through wide-ranging research agreements. If the partner liked anything arising from the research, it had the first right to license it.

TSRI actually got into trouble for a deal that was too big. The proposed deal, announced in 1992, would have brought the institute $300 million over 10 years. The money was to be provided by Sandoz, a predecessor to Swiss pharma giant Novartis. In return, Sandoz would have the first right to license any technologies emerging from Scripps Research.

That deal was a big boost from an expiring $116 million deal with Johnson & Johnson. But its all-encompassing scope drew opposition from public officials, such as Bernadine Healy, then director of the National Institutes of Health, and Ron Wyden, then a Democratic congressman from Oregon and now a U.S. senator.

The opposition forced the parties to scale back the transaction. The revised deal gave Scripps $20 million over five years, with an option to renew for another five years. In return, Sandoz got first right to license nearly half of TSRI’s technology.

While the terms were narrowed, the deal itself followed the same format: In return for promising technology, Sandoz would pay to commercialize it.

That approach, which was used at other research institutions, later fell out of favor because it was too risky for the drug companies. These companies paid millions expecting that research would yield profitable drugs, providing a good return on investment.

However, most research doesn’t lead to drugs or other therapies. Often, research doesn’t yield a drug that can be tested in people. And even when drugs enter clinical testing, the great majority never complete it.

One recent study from Massachusetts Institute of Technology scientists found that just 13.8 percent of drugs that enter clinical testing end up getting approved by the U.S. Food and Drugs Administration. Previous estimates were even lower.

More importantly, the drug companies’ profits from the few successes wasn’t high enough to make up for the expensive failures. So they have become much more selective in negotiating deals, requiring more evidence for their money.

At the same time, government research funding has become harder to come by. This has placed Scripps, and other institutions, in a financial squeeze. To date, private philanthropy hasn’t filled the gap.

And an attempt several years ago to secure funding from the University of Southern California foundered on concerns TSRI was surrendering its independence. That led to the departure of Michael Marletta as institute president in 2014, and ultimately, to Schultz taking over.

Under Schultz, TSRI’s answer is to advance further into the drug companies own turf, stopping short of actually marketing products.

This requires the institute to take on more risk, counting on its technological expertise to manage that risk. And in return for getting actual drugs and not just research, the partners should be willing to pay TSRI more.

That’s the calculation with the arthritis drug. Instead of licensing complicated research that’s a long way from any product, the drug itself is a tangible medicine that addresses one of humanity’s common afflictions — if it works.

Related reading

Scripps Research CEO outlines path to financial stability

Scripps Research projects $21M deficit

Scripps signs licensing deal with Pfizer

Scripps’ Latest Deal Sparks Debate : Research: Critics fault taxpayer- funded lab for giving a foreign firm first crack at technology

Scripps Signs $300-Million Agreement : Medicine: Under deal, research institute will give right of first refusal to Sandoz Pharmaceuticals.

NIH ANALYSIS OF SCRIPPS-SANDOZ

Science Playlist

In a first, scientists rid human embryos of a potentially fatal gene mutation by editing their DNA On Now

In a first, scientists rid human embryos of a potentially fatal gene mutation by editing their DNA

10 interesting facts about Mars On Now

10 interesting facts about Mars

Kids can add years to your life On Now

Kids can add years to your life

LA 90: SpaceX launches recycled rocket On Now

LA 90: SpaceX launches recycled rocket

Ocean temperatures warming at rapid rate, study finds On Now

Ocean temperatures warming at rapid rate, study finds

bradley.fikes@sduniontribune.com

(619) 293-1020